CClinicalTrials.gg
CompletedNCT05352555Updated Apr 29, 2022

Automated Robotic Maneuvering System (RMS) vs Manual Reposition Maneuver in Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

A Phase 1/2 interventional study of Automated vertigo repositioning chair and Canalith Reposition Maneuver in Benign Paroxysmal Positional Vertigo, sponsored by Stratejik Yenilikci Girisimler Ltd.. Completed at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Stratejik Yenilikci Girisimler Ltd. · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Comparison of treatment efficacy of an automated robotic maneuvering system (RMS) repositioning chair versus manual positioning maneuvers in Benign Paroxysmal Positional Vertigo.

Read the detailed description

The standard treatments for Benign Paroxysmal Positional Vertigo (BPPV) are manual positioning maneuvers. This method, beyond being costly and requiring extensive training, is a significant burden on healthcare resources. We developed an automated robotic maneuvering system, hereby known as RMS, to tackle this problem. Our Clinical Investigation is two-fold; (1) test the safety of RMS and, (2) understand the viability of RMS for treating BPPV when compared to manual positioning maneuvers.

02

Conditions studied

  • Benign Paroxysmal Positional Vertigo

Keywords

  • Automated
  • Robotic
  • Vertigo
  • Epley maneuver
  • RMS chair
  • Reposition chair
  • Dizziness
  • Vestibular diseases
  • Multi canal BPPV
03

In context

Vertigo

248 studies on the registry are indexed under Vertigo; 39 are open to participants now.

This study's enrollment of 75 is above the median of 57 across 186 interventional studies indexed under Vertigo.

Browse Vertigo studies →

Lead sponsor

Stratejik Yenilikci Girisimler Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Characteristic positional nystagmus (for BPPV)
  • Positive Dix-Hallpike
  • Positive supine roll test
  • Positive Deep Head Hanging
  • Vertigo-Dizziness Imbalance symptom scores compatible with BPPV

Exclusion criteria

Exclusion Criteria:

  • Pregnant patients
  • Patients who have taken vertigo suppressing agents (Dimenhydrinate) in the last 48 hours
  • Patients taller than 200 cm (2.0 m)
  • Patients who have had a cardiovascular or neurosurgical operation in the last month
  • Patients with retinal detachment and/or glaucoma
  • Lack of treatment cooperation
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Robotic Maneuvering System (RMS)

    BPPV subtype diagnosis and corresponding treatment will be performed using automated RMS chair and recorded with video frenzel goggle. In cases of posterior canal involvement, Epley's maneuver will be used for canalithiasis and cupulolithiasis. Semont maneuver will be used as a second-line treatment for cupulolithiasis, in cases of initial failure. In cases of horizontal canal involvement, Barbecue (Lempert) maneuver will be used. If canalithiasis or cupulolithiasis is diagnosed, Gufoni's maneuver will be performed. In cases of anterior canal involvement, Yacovino's maneuver will be used.

    Device: Automated vertigo repositioning chair

  • Active comparator
    Canalith Reposition Maneuver

    BPPV subtype diagnosis and corresponding treatment will be performed with manual repositioning maneuvers and recorded with video frenzel goggle. In cases of posterior canal involvement, Epley's maneuver will be used. In cases of horizontal canal involvement, Log roll maneuver will be used. In cases of anterior canal involvement, Yacovino's maneuver will be used.

    Other: Canalith Reposition Maneuver

Interventions

  • DeviceAutomated vertigo repositioning chair

    Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn. Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below). 1. Dix-Hallpike (for posterior canal involvement) 2. Supine roll (for horizontal canal involvement) 3. (Optional) Deep Head Hanging (for anterior canal involvement) If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below). 1. Epley's and/or Semont's maneuver (for posterior canal involvement) 2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement) 3. Yacovino's maneuver (for anterior canal involvement) 10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention. A follow-up was done one week later at the earliest.

    Also known as: Robotic Maneuvering System (RMS)

  • OtherCanalith Reposition Maneuver

    Patients were seated on a examination table and given videonystagmography goggles (VNG). Manual diagnostic procedures are performed to determine vertigo subtype and orientation. The manual diagnostic procedures for Left and Right sided semicircular canals are: 1. Dix-Hallpike (for posterior canal involvement) 2. Supine roll and Bow and Lean (for horizontal canal involvement) If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually. The automated treatment maneuvers are: 1. Epley's maneuver (for posterior canal involvement) 2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement) Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention. A second follow-up was done one week later at the earliest.

    Also known as: Manual Reposition Maneuver

06

What researchers measure

Primary outcomes

  1. Number of Treatments

    Number of treatment necessary to achieve resolution of vertigo and nystagmus

    Time frame: 1 month (30 days)

  2. Treatment success

    Number of subjects achieving resolution of vertigo and nystagmus after one treatment

    Time frame: After treatment: 1 week - 1 month (30 days)

Secondary outcomes

  1. Vertigo-Dizziness Imbalance (VDI) questionnaire

    Comparison of pre-treatment and post-treatment score based on symptoms and quality of life

    Time frame: 1 month (30 days)

  2. Adverse events

    Registration of adverse events and safety issues related to RMS.

    Time frame: 1 month (30 days)

07

Study locations

1 site
  • Haseki Sultangazi Training and Research Hospital
    Istanbul, Sultangazi 34265, Turkey
08

References and documents

Publications

  • Tan J, Yu D, Feng Y, Song Q, You J, Shi H, Yin S. Comparative study of the efficacy of the canalith repositioning procedure versus the vertigo treatment and rehabilitation chair. Acta Otolaryngol. 2014 Jul;134(7):704-8. doi: 10.3109/00016489.2014.899711. Epub 2014 May 7. PubMed 24807849 ↗
  • Choung YH, Shin YR, Kahng H, Park K, Choi SJ. 'Bow and lean test' to determine the affected ear of horizontal canal benign paroxysmal positional vertigo. Laryngoscope. 2006 Oct;116(10):1776-81. doi: 10.1097/01.mlg.0000231291.44818.be. PubMed 17003735 ↗
  • West N, Hansen S, Moller MN, Bloch SL, Klokker M. Repositioning chairs in benign paroxysmal positional vertigo: implications and clinical outcome. Eur Arch Otorhinolaryngol. 2016 Mar;273(3):573-80. doi: 10.1007/s00405-015-3583-z. Epub 2015 Mar 7. PubMed 25749489 ↗
  • Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston LJ, Cass S, Chalian AA, Desmond AL, Earll JM, Fife TD, Fuller DC, Judge JO, Mann NR, Rosenfeld RM, Schuring LT, Steiner RW, Whitney SL, Haidari J; American Academy of Otolaryngology-Head and Neck Surgery Foundation. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2008 Nov;139(5 Suppl 4):S47-81. doi: 10.1016/j.otohns.2008.08.022. PubMed 18973840 ↗
  • Pedersen MF, Eriksen HH, Kjaersgaard JB, Abrahamsen ER, Hougaard DD. Treatment of Benign Paroxysmal Positional Vertigo with the TRV Reposition Chair. J Int Adv Otol. 2020 Aug;16(2):176-182. doi: 10.5152/iao.2020.6320. PubMed 32784154 ↗
  • Nakayama M, Epley JM. BPPV and variants: improved treatment results with automated, nystagmus-based repositioning. Otolaryngol Head Neck Surg. 2005 Jul;133(1):107-12. doi: 10.1016/j.otohns.2005.03.027. PubMed 16025062 ↗
  • Richard-Vitton T, Seidermann L, Fraget P, Mouillet J, Astier P, Chays A. [Benign positional vertigo, an armchair for diagnosis and for treatment: description and significance]. Rev Laryngol Otol Rhinol (Bord). 2005;126(4):249-51. French. PubMed 16496552 ↗
  • Yanik B, Kulcu DG, Kurtais Y, Boynukalin S, Kurtarah H, Gokmen D. The reliability and validity of the Vertigo Symptom Scale and the Vertigo Dizziness Imbalance Questionnaires in a Turkish patient population with benign paroxysmal positional vertigo. J Vestib Res. 2008;18(2-3):159-70. PubMed 19126986 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05352555
Lead sponsor
Stratejik Yenilikci Girisimler Ltd.
Collaborators
Haseki Sultangazi Teaching and Research Hospital, University of Health Sciences
Responsible party
Murat Haluk Ozkul (Chief Medical Officer (CMO), Stratejik Yenilikci Girisimler Ltd.) — Principal investigator
First posted
Apr 29, 2022
Start date
Feb 15, 2022
Primary completion
Apr 12, 2022
Completion
Apr 23, 2022
Last update
Apr 29, 2022

Study contacts

Murat H Ozkul, M.D.
principal investigator · StatejikYG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion